{"id":"cridanimod","rwe":[{"pmid":"40917098","year":"2025","title":"Repurposing of Anti-Infectives for the Management of Onchocerciasis Using Machine Learning and Protein Docking Studies.","finding":"","journal":"Bioinformatics and biology insights","studyType":"Clinical Study"},{"pmid":"37630394","year":"2023","title":"Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"35631443","year":"2022","title":"Tilorone and Cridanimod Protect Mice and Show Antiviral Activity in Rats despite Absence of the Interferon-Inducing Effect in Rats.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"}],"tags":[{"label":"cridanimod","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L03AX18","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"neovir","offLabel":[],"synonyms":["cridanimod","neovir","sodium cridanimod","oxodihydroacridinylacetate sodium"],"timeline":[],"approvals":[],"brandName":"Neovir","ecosystem":[],"mechanism":{"target":"Stimulator of interferon genes protein, Trypsin","modality":"Small Molecule","drugClass":"cridanimod","explanation":"Imagine your immune system is like a security guard that protects you from harm. Neovir helps the guard work more efficiently by fine-tuning its response to threats, reducing unnecessary inflammation and damage. This can help alleviate symptoms and improve outcomes for patients with certain conditions.","oneSentence":"Neovir works by modulating the immune system to treat a specific condition.","technicalDetail":"Neovir, a cridanimod, is a small molecule that interacts with specific immune system pathways to modulate the immune response, potentially offering therapeutic benefits for conditions characterized by immune dysregulation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4853","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CRIDANIMOD","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CRIDANIMOD","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:22:46.724550","biosimilars":[],"competitors":[{"drugName":"pegademase","drugSlug":"pegademase","fdaApproval":"1990-03-21","relationship":"same-class"},{"drugName":"glatiramer acetate","drugSlug":"glatiramer-acetate","fdaApproval":"1996-12-20","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plerixafor","drugSlug":"plerixafor","fdaApproval":"2008-12-15","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elapegademase","drugSlug":"elapegademase","fdaApproval":"2018-10-05","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cridanimod","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pegademase","brandName":"pegademase","genericName":"pegademase","approvalYear":"1990","relationship":"same-class"},{"drugId":"glatiramer-acetate","brandName":"glatiramer acetate","genericName":"glatiramer acetate","approvalYear":"1996","relationship":"same-class"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-class"},{"drugId":"plerixafor","brandName":"plerixafor","genericName":"plerixafor","approvalYear":"2008","relationship":"same-class"},{"drugId":"elapegademase","brandName":"elapegademase","genericName":"elapegademase","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06183229","phase":"PHASE3","title":"Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-09-15","conditions":["Influenza","Acute Respiratory Infection"],"enrollment":166,"completionDate":"2024-06-10"},{"nctId":"NCT03077698","phase":"PHASE2","title":"An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer","status":"TERMINATED","sponsor":"Xenetic Biosciences, Inc.","startDate":"2017-06-14","conditions":["Endometrial Cancer"],"enrollment":25,"completionDate":"2020-07-17"},{"nctId":"NCT02064725","phase":"PHASE2","title":"Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA","status":"UNKNOWN","sponsor":"Kevelt AS","startDate":"2014-09","conditions":["Recurrent or Persistent Endometrial Carcinoma"],"enrollment":8,"completionDate":"2018-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"X91E9EME19","CHEBI":"CHEBI:136036","INN_ID":"8018","UMLSCUI":"C0044659","ChEMBL_ID":"CHEMBL1569545","KEGG_DRUG":"D10507","DRUGBANK_ID":"DB13674","PDB_CHEM_ID":"1K5","PUBCHEM_CID":"38072","MESH_SUPPLEMENTAL_RECORD_UI":"C077681"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"L03AX18","allCodes":["L03AX18"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025","pmid":"40917098","title":"Repurposing of Anti-Infectives for the Management of Onchocerciasis Using Machine Learning and Protein Docking Studies.","journal":"Bioinformatics and biology insights"},{"date":"2023 Aug 19","pmid":"37630394","title":"Glycyrrhiza glabra L. Extracts and Other Therapeutics against SARS-CoV-2 in Central Eurasia: Available but Overlooked.","journal":"Molecules (Basel, Switzerland)"},{"date":"2022 May 17","pmid":"35631443","title":"Tilorone and Cridanimod Protect Mice and Show Antiviral Activity in Rats despite Absence of the Interferon-Inducing Effect in Rats.","journal":"Pharmaceuticals (Basel, Switzerland)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neovir, also known as Cridanimod, is a small molecule drug in the cridanimod class. Its original development is attributed to an unknown entity, and it is currently owned by an unspecified company. The target and indications for Neovir are not publicly disclosed, and its commercial status, including patent and generic availability, is unknown. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also not available. Further information on Neovir's safety profile and efficacy is required to fully understand its clinical utility.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}